Laboratory of Molecular Endocrinology and Metabolism, Department of Molecular Medicine, Institute for Molecular and Cellular Regulation, Gunma University, Gunma 371-8512, Japan.
Endocr J. 2023 Aug 28;70(8):761-770. doi: 10.1507/endocrj.EJ23-0112. Epub 2023 Apr 19.
ALK7, a type I receptor for the transforming growth factor-β superfamily, is known to be predominantly expressed in adipocytes in both mice and humans. The present review describes recent findings suggesting that ALK7 plays a major role in regulating lipid metabolism and fat mass. Furthermore, the ligands and upstream regulators that activate ALK7 signaling are discussed. The focus is on findings in mice and their derivative tissues and cells that harbor the mutations of ALK7 and related molecules. Particular attention is paid to the contradictory nature of the current literature about the loss-of-function phenotypes and the relationship with insulin secretion and sensitivity. Additional attention is paid to the ALK7 gene variants found in humans and their associated traits. The goal is to seek a parsimonious, and preferably singular and unified, description of the underlying mechanism. This review also introduces recent promising findings about ALK7 neutralizing treatment to obese mice.
ALK7 是转化生长因子-β 超家族的 I 型受体,在人和小鼠的脂肪细胞中均有较高表达。本综述描述了最近的研究结果,表明 ALK7 在调节脂代谢和脂肪量方面起着重要作用。此外,还讨论了激活 ALK7 信号的配体和上游调节剂。重点介绍了在携带 ALK7 和相关分子突变的小鼠及其衍生组织和细胞中的发现。特别关注目前关于失活表型与胰岛素分泌和敏感性之间关系的文献的矛盾性质。还关注了在人类中发现的 ALK7 基因变异及其相关特征。目标是寻求一个简洁的、最好是单一且统一的基础机制描述。本综述还介绍了最近关于肥胖小鼠中 ALK7 中和治疗的有希望的发现。